We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-22.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$402M
AUM Growth
-$164M
Cap. Flow
+$47.9M
Cap. Flow %
11.9%
Top 10 Hldgs %
62.89%
Holding
86
New
14
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$55.3M
2
AMRN
Amarin Corp
AMRN
+$43M
3
TGTX icon
TG Therapeutics
TGTX
+$21.3M
4
APLS
Apellis Pharmaceuticals
APLS
+$20.9M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$15.8M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$21.9M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$18.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$16M
4
ENSG icon
The Ensign Group
ENSG
+$14M
5
SNY icon
Sanofi
SNY
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 92.24%
2 Miscellaneous 5.59%
3 Communication Services 2.07%
4 Financials 0.11%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$49.8M 12.38%
2,013,467
+1,517,822
+306% +$55.3M
DHR icon
2
Danaher
DHR
$152B
$32.4M 8.06%
263,903
+41,566
+19% +$5.6M
ASND icon
3
Ascendis Pharma A/S
ASND
$16.3B
$31M 7.71%
275,494
+72,600
+36% +$9.43M
TGTX icon
4
TG Therapeutics
TGTX
$8.26B
$24.2M 6.02%
2,461,137
+1,684,814
+217% +$21.3M
APLS
5
DELISTED
Apellis Pharmaceuticals
APLS
$24.1M 5.99%
899,474
+589,065
+190% +$20.9M
CCXI
6
DELISTED
ChemoCentryx, Inc.
CCXI
$23.3M 5.79%
580,011
+66,822
+13% +$2.84M
GSK icon
7
GSK
GSK
$102B
$19.9M 4.94%
408,457
-410,011
-50% -$21.9M
DCPH
8
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17M 4.24%
414,081
+285,333
+222% +$15.8M
AZN icon
9
AstraZeneca
AZN
$252B
$15.7M 3.91%
176,276
+105,995
+151% +$9.98M
SPY icon
10
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$15.5M 3.84%
60,000
-100,000
-63% -$30.5M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.51B
$15.1M 3.75%
7,542,372
+2,637,912
+54% +$7.26M
AMRN
12
Amarin Corp
AMRN
$295M
$14M 3.48%
175,203
+129,423
+283% +$43M
ENSG icon
13
The Ensign Group
ENSG
$10.1B
$13.4M 3.34%
357,028
-319,030
-47% -$14M
HCA icon
14
HCA Healthcare
HCA
$90.5B
$9.07M 2.26%
+101,000
New +$13.1M
MODN
15
DELISTED
MODEL N, INC.
MODN
$8.31M 2.07%
374,284
+166,669
+80% +$4.87M
SNY icon
16
Sanofi
SNY
$107B
$8.29M 2.06%
189,578
-252,083
-57% -$12.1M
FATE icon
17
Fate Therapeutics
FATE
$291M
$6.78M 1.69%
305,485
-55,171
-15% -$1.4M
DXCM icon
18
DexCom
DXCM
$34.3B
$5.26M 1.31%
78,148
+29,948
+62% +$1.86M
TARO
19
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$4.68M 1.16%
76,459
+71,506
+1,444% +$5.3M
AMRN
20
CALL
Amarin Corp
AMRN
$295M
$4.09M 1.02%
51,180
+1,470
+3% +$488K
KDMN
21
DELISTED
Kadmon Holdings, Inc.
KDMN
$4.09M 1.02%
975,350
-166,589
-15% -$717K
PNTG icon
22
Pennant Group
PNTG
$1.3B
$4M 0.99%
282,181
-89,012
-24% -$2.25M
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.99M 0.99%
+146,550
New +$4.08M
RDUS
24
DELISTED
Radius Health, Inc.
RDUS
$3.91M 0.97%
301,073
-17,738
-6% -$316K
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$3.8M 0.95%
+42,305
New +$3.29M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2020 Portfolio in Review

As of Q1 2020, Eversept Partners held 86 positions worth $402M, down 29% from $566M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $47.9M of net new capital in Q1 2020, opening 14 new positions and adding to 17 existing holdings. Its largest new stake was HCA Healthcare: 101,000 shares worth $9.07M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was GSK, an estimated $21.9M trimmed.

  • Eversept Partners's largest Q1 2020 buy was HCA Healthcare: 101,000 shares worth $9.07M.
  • Eversept Partners added most to Zogenix, Inc. in Q1 2020, an estimated $55.3M increase.
  • Eversept Partners's biggest Q1 2020 reduction was GSK, cutting an estimated $21.9M.
  • Eversept Partners fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $18.3M.
  • Eversept Partners's ten largest holdings make up 63% of its $402M portfolio in Q1 2020.
  • Eversept Partners opened 14 new positions and closed 25 in Q1 2020.
  • Eversept Partners's portfolio value fell 29% quarter-over-quarter to $402M.

Based on Eversept Partners's 13F filing for Q1 2020, filed 13 May 2020.